Caspofungin is the first licensed echinocandin antifungal, inhibiting 1,3-alpha-glucan synthase to disrupt fungal cell-wall integrity, used intravenously for invasive aspergillosis and candidiasis. Simson Pharma's Caspofungin reference standard and impurities support the demanding potency and stability-indicating testing required of this critical-care antifungal.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Caspofungin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.